Prospects for therapeutic inhibition of neuroblastoma angiogenesis

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 171-179

  Shusterman, Suzanne ^a,b   Maris, John M ^c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Angiogenesis inhibition; MetAP2; Neuroblastoma; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; A 357300; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; ENZYME INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; IMATINIB; ISOTRETINOIN; METHIONINE AMINOPEPTIDASE INHIBITOR; METHIONYL AMINOPEPTIDASE; PEGAPTANIB; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VASCULOTROPIN TRAP;

ANGIOGENESIS; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; METASTASIS; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 23944470359     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.049     Document Type: Review

References (47)

1. G.M. Brodeur, and J.M. Maris Neuroblastoma P.A. Pizzo D.G. Poplack Principles and Practice of Pediatric Oncology 2002 2002 J.B. Lippincott Company Philadelphia 895 938
2. K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, and N.K. Ramsay Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N. Engl. J. Med. 341 1999 1165 1173
3. A.T. Meadows, and Y. Tsunematsu Late effects of treatment for neuroblastoma G.M. Brodeur T. Sawada Y. Tsuchida P.A. Voute Neuroblastoma 2000 2000 Elsevier Science B.V Amsterdam 561 570
4. A. Canete, S. Navarro, J. Bermudez, A. Pellin, V. Castel, and A. Llombart-Bosch Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients J. Clin. Oncol. 18 2000 27 34
5. H.M. Katzenstein, S.L. Cohn, S. Crawford, and D. Meitar Angiogenesis in neuroblastoma J. Clin. Oncol. 18 2000 2789 2791
6. D. Meitar, S.E. Crawford, A.W. Rademaker, and S.L. Cohn Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma J. Clin. Oncol. 14 1996 405 414
7. D. Huang, J.L. Rutkowski, G.M. Brodeur, P.M. Chou, J.L. Kwiatkowski, A. Babbo, and S.L. Cohn Schwann cell-conditioned medium inhibits angiogenesis Cancer Res. 60 2000 5966 5971
8. A. Chlenski, S. Liu, S.E. Crawford, O.V. Volpert, G.H. DeVries, and A. Evangelista SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis Cancer Res. 62 2002 7357 7363
9. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat. Med. 6 2000 389 395
10. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
11. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
12. B. Meister, F. Grunebach, F. Bautz, W. Brugger, F.M. Fink, L. Kanz, and R. Mohle Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma Eur. J. Cancer 35 1999 445 449
13. I. Langer, P. Vertongen, J. Perret, J. Fontaine, G. Atassi, and P. Robberecht Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas Med. Pediatr. Oncol. 34 2000 386 393
14. A. Eggert, M.A. Grotzer, N. Ikegaki, X.G. Liu, A.E. Evans, and G.M. Brodeur Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells Cancer Res. 62 2002 1802 1808
15. E.S. Kim, A. Serur, J. Huang, C.A. Manley, K.W. McCrudden, and J.S. Frischer Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc. Natl Acad. Sci. USA 99 2002 11399 11404
16. A. Eggert, N. Ikegaki, J. Kwiatkowski, H. Zhao, G.M. Brodeur, and B.P. Himelstein High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas Clin. Cancer Res. 6 2000 1900 1908
17. A. Erdreich-Epstein, H. Shimada, S. Groshen, M. Liu, L.S. Metelitsa, and K.S. Kim Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide Cancer Res. 60 2000 712 721
18. C.F. Chantrain, H. Shimada, S. Jodele, S. Groshen, W. Ye, and D.R. Shalinsky Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment Cancer Res. 64 2004 1675 1686
19. Y. Sugiura, H. Shimada, R.C. Seeger, W.E. Laug, and Y.A. DeClerck Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis Cancer Res. 58 1998 2209 2216
20. T. Fotsis, S. Breit, W. Lutz, J. Rossler, E. Hatzi, M. Schwab, and L. Schweigerer Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells Eur. J. Biochem. 263 1999 757 764
21. S. Breit, J. Rossler, T. Fotsis, and L. Schweigerer N-myc down-regulates activin A Biochem. Biophys. Res. Commun. 274 2000 405 409
22. H. Shimada, J. Chatten, W. Newton Jr, N. Sachs, A.B. Hamoudi, and T. Chiba Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas J. Natl Cancer Inst. 73 1984 405 416
23. I.M. Ambros, A. Zellner, B. Roald, G. Amann, R. Ladenstein, and D. Printz Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma, N Engl. J. Med. 334 1996 1505 1511
24. J. Huang, J.S. Frischer, A. Serur, A. Kadenhe, A. Yokoi, and K.W. McCrudden Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc. Natl Acad. Sci. USA 100 2003 7785 7790
25. T.A. Fong, L.K. Shawver, L. Sun, C. Tang, H. App, and T.J. Powell SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res. 59 1999 99 106
26. S. Shusterman, R. Barr, G. McMahon, and J.M. Maris Inhibition of the VEGF, PDGF, and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42 2001 803
27. E. Kim, J. Moore, J. Huang, S. Soffer, C.A. Manley, and K. O'Toole All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor J. Pediatr. Surg. 36 2001 287 290
28. K. Beppu, J. Jaboine, M.S. Merchant, C.L. Mackall, and C.J. Thiele Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression J. Natl. Cancer Inst. 96 2004 46 55
29. H. Endo, K. Takenaga, T. Kanno, H. Satoh, and S. Mori Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4 J. Biol. Chem. 277 2002 26396 26402
30. R.A. Bradshaw, W.W. Brickey, and K.W. Walker N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families Trends Biochem. Sci. 23 1998 263 267
31. A. Catalano, M. Romano, I. Robuffo, L. Strizzi, and A. Procopio Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity Am. J. Pathol. 159 2001 721 731
32. J. Wang, G.S. Sheppard, P. Lou, M. Kawai, N. BaMaung, and S.A. Erickson Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2 Cancer Res. 63 2003 7861 7869
33. E. Nagabuchi, W.E. VanderKolk, Y. Une, and M.M. Ziegler TNP-470 antiangiogenic therapy for advanced murine neuroblastoma J. Pediatr. Surg. 32 1997 287 293
34. E. Wassberg, S. Pahlman, J.E. Westlin, and R. Christofferson The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats Pediatr. Res. 41 1997 327 333
35. H.M. Katzenstein, A.W. Rademaker, C. Senger, H.R. Salwen, N.N. Nguyen, and P.S. Thorner Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden Clin. Cancer Res. 5 1999 4273 4278
36. S. Shusterman, S.A. Grupp, R. Barr, D. Carpentieri, H. Zhao, and J.M. Maris The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease, Clin Cancer Res. 7 2001 977 984
37. J. Yoshizawa, R. Mizuno, T. Yoshida, A. Hara, S. Ashizuka, and M. Kanai Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma J. Surg. Res. 93 2000 82 87
38. W.M. Stadler, T. Kuzel, C. Shapiro, J. Sosman, J. Clark, and N.J. Vogelzang Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma J. Clin. Oncol. 17 1999 2541 2545
39. C.J. Logothetis, K.K. Wu, L.D. Finn, D. Daliani, W. Figg, H. Ghaddar, and J.U. Gutterman Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin. Cancer Res. 7 2001 1198 1203
40. M.J. Morowitz, R. Barr, Q. Wang, R. King, N. Rhodin, B. Pawel, et al. Methionine Aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models, Clin. Cancer Res. in press, 2005.
41. W.A. Weiss, K. Aldape, G. Mohapatra, B.G. Feuerstein, and J.M. Bishop Targeted expression of MYCN causes neuroblastoma in transgenic mice EMBO J. 1997 2985 2995
42. W.A. Weiss, T. Godfrey, C. Francisco, and J.M. Bishop Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma Cancer Res. 60 2000 2483 2487
43. M.P. La Quaglia, B.H. Kushner, G. Heller, M.A. Bonilla, K.L. Lindsley, and N.K. Cheung Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome J Pediatr. Surg. 29 1994 1162 1165
44. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, and D.J. Hicklin Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
45. T. Browder, C.E. Butterfield, B.M. Kraling, B. Shi, B. Marshall, M.S. O'Reilly, and J. Folkman Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 2000 1878 1886
46. G. Bocci, G. Francia, S. Man, J. Lawler, and R.S. Kerbel Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy, Proc Natl Acad. Sci. USA 100 2003 12917 12922
47. J. Folkman Endogenous angiogenesis inhibitors APMIS 112 2004 496 507